Heiko Schoder

Sloan-Kettering Inst Can Research

$1,187,229

Attributed

$3,119,181

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $720.4K · FY2012–25

$1M$750K$500K$250K$0

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$3,119,181 · 2

By mechanism

U01$1,699,454 · 1

R01$1,419,727 · 1

Top collaborators

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Ping Mu$4,365,544
Richard N Kolesnick$17,601,323
Jan Grimm$17,140,928
Brett Stewart Carver$12,016,524
Charles L Sawyers$34,701,646

Others in their field

Top investigators on “Tumor Tissue”

David Heimbrook · Leidos Biomedical Research, Inc.$329,212,748
Timothy J Eberlein · Washington University$86,792,803
Larry Arthur$85,804,691
Richard L Schilsky · University Of Chicago$80,448,107
Monica M Bertagnolli · Strang Cancer Prevention Center$75,743,395
Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$72,731,981

Research focus

Tumor TissueTumorMalignant NeoplasmsMeasurementChemotherapyFutureImagePositron-Emission TomographyNon-Invasive ImagingAnimal TissueBiopsyBioluminescence ImagingBloodBlood VesselsAnimal ExperimentsAffectBaseCar T Cell TherapyCancer TypeApoptosisCastrationCell SurfaceCharacteristicsAndrogens

Grant awards (5)

Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy$699,311

R01 · FY2025 · CA

Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy$720,416

R01 · FY2024 · CA

Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT$486,303

U01 · FY2014 · CA

Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT$583,127

U01 · FY2013 · CA

Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT$630,024

U01 · FY2012 · CA